Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Pre-existing cytotoxic capacity of CD8+ and CD4+ T cells is a hallmark of richter transformation and favors response to anti-PD-1 therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJohan E. GustafssonCTChiara TomasoniGHGabriela Brunsting Hoffmann

Discussion

Loading...

Member takes

Overview

Observational analysis highlighted tumor mutational burden and cytotoxic T cells in Richter Transformation, indicating T-cell characteristics influence anti-PD-1 therapy response.

Key Points

  • Tumor mutational burden was higher in Richter Transformation models compared to chronic lymphocytic leukemia, suggesting strong immune landscape differences.
  • Single-cell RNA sequencing revealed enriched cytotoxic T cells and pro-inflammatory macrophages in Richter Transformation mouse models.
  • Immunofluorescence staining of lymph node biopsies revealed distinct immune aggregate patterns in responders versus non-responders.
  • Findings suggest that preserved T-cell function and spatial immunity contribute to immune checkpoint blockade efficacy in Richter Transformation.

Cite This Study

Gustafsson et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc7ehttps://doi.org/10.1182/blood-2025-243
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial2025
  2. 2Immune exhaustion limits CD19 CAR-T efficacy in Richter's transformation2025
  3. 3Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy2025
  4. 4Pre-treatment immune profiling by flow cytometry and single-cell transcriptomics identifies distinct features in B and T cells in rituximab responders and non-responders2025
  5. 5Abstract PR-13: Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression2025